Galena Biopharma fka GALE

[Euripides90]

Another hit piece/ faux article from someone else at The Street yesterday -- claiming no association to Crummer & Associates.

By David Aferiat 06/16/14 - 10:22 AM EDT

Just who is this David Aferiat?
Not like he has personal interest in trading GALE, right?
Here's just one former reference from his "Tradeideas" blog:

http://stocktwits.com/TradeIdeas

self-described "swing trader."


Feb. 12 at 9:42 AM
TradeIdeas

David Aferiat
in Chicago for meetings today. Eyes on $GALE on this pullback and ending my trade in $ASYS basically even #portfoliorinse
Symbols (2) Current Price Since Messaged
GALE
Galena Biopharma,

Feb. 14th: "Late on bailing out of GALE."
At $2.86 back to where we were 4 mos. ago but with crucial differences in the future of the stock?

http://stocktwits.com/TradeIdeas/message/20085540


Back to yesterday's "article:"

This bizarrely self-contradictory piece quotes a number of reasons GALE is showing strong growth while claiming it's a sell due to low return on equity -- yeah sure, if they keep hammering the stock to short it.
"The stock has a beta of 1.05 and a short float of 22.2% with 4.51 days to cover. Shares are down 41.7% year-to-date as of the close of trading on Friday."


"Highlights from the ratings report include:

The declining revenue has not hurt the company's bottom line, with increasing earnings per share.

Net operating cash flow has significantly decreased to -$8.05 million or 50.96% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.

GALENA BIOPHARMA INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, GALENA BIOPHARMA INC reported poor results of -$0.79 versus -$0.62 in the prior year. This year, the market expects an improvement in earnings (-$0.30 versus -$0.79).

The gross profit margin for GALENA BIOPHARMA INC is currently very high, coming in at 91.26%. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -116.70% is in-line with the industry average.

The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Biotechnology industry. The net income increased by 72.7% when compared to the same quarter one year prior, rising from -$9.29 million to -$2.54 million."